title: Antipsychotics promote the differentiation of oligodendrocyte progenitor cells by regulating oligodendrocyte lineage transcription factors 1 and 2.
abstract: OBJECTIVE
  Oligodendrocyte/myelin abnormalities may be an important component of the pathogenesis found in schizophrenia. The aim of this current study was to examine the possible effects of the antipsychotic drugs (APDs) haloperidol (HAL), olanzapine (OLA), and quetiapine (QUE) on the development of oligodendroglial lineage cells.
  
  
  METHODS
  CG4 cells, an oligodendrocyte progenitor cell line, were treated with various concentrations of HAL, OLA, or QUE for specific periods. The proliferation and differentiation of the CG4 cells were measured. The regulation of CG4 cell differentiation by oligodendrocyte lineage transcription factors 1 and 2 (Olig1 and Olig2) was examined.
  
  
  RESULTS
  The APDs used in this study had no effect on the proliferation of CG4 cells. The APDs elevated the expression of 2',3'-cyclic nucleotide 3'-phosphodiesterase (CNP), a specific marker of oligodendrocytes, and promoted the CG4 cells to differentiate into CNP positive oligodendrocytes. QUE and OLA increased the expression of both Olig1 and Olig2 whereas HAL only increased the expression of Olig2.
  
  
  CONCLUSIONS
  Our findings suggest that oligodendrocyte development is a target of HAL, OLA, and QUE and provide further evidence of the important role of oligodendrocytes in the pathophysiology and treatment of schizophrenia. They also indicate that the expression level of oligodendrocyte/myelin-related genes could be profoundly affected by APDs, which should be considered in future studies aiming to measure the oligodendrocyte/myelin-related gene expressions in schizophrenia patients.
authors: Department of Nutrition, School of Public Health, Jilin University, 1163 Ximin Street, Changchun, China.
authors: Fang
authors: F
authors: Fang
authors: Handi
authors: H
authors: Zhang
authors: Yanbo
authors: Y
authors: Zhang
authors: Haiyun
authors: H
authors: Xu
authors: Qingjun
authors: Q
authors: Huang
authors: Abulimiti
authors: A
authors: Adilijiang
authors: Junhui
authors: J
authors: Wang
authors: Zhijun
authors: Z
authors: Zhang
authors: Dai
authors: D
authors: Zhang
authors: Qingrong
authors: Q
authors: Tan
authors: Jue
authors: J
authors: He
authors: Lynda
authors: L
authors: Kong
authors: Ya
authors: Y
authors: Liu
authors: Xin-Min
authors: XM
authors: Li
mesh_terms: D063309:2',3'-Cyclic Nucleotide 3'-Phosphodiesterase / Q000378:metabolism; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D051792:Basic Helix-Loop-Helix Proteins / Q000235:genetics / Q000378:metabolism*; D001569:Benzodiazepines / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects*; D002460:Cell Line; D049109:Cell Proliferation; D003987:Dibenzothiazepines / Q000494:pharmacology; D015870:Gene Expression / Q000187:drug effects; D006220:Haloperidol / Q000494:pharmacology; D006801:Humans; D051379:Mice; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000378:metabolism*; D058953:Neural Stem Cells / Q000187:drug effects / Q000502:physiology*; D000077152:Olanzapine; D000076104:Oligodendrocyte Transcription Factor 2; D009836:Oligodendroglia / Q000378:metabolism*; D000069348:Quetiapine Fumarate; D051381:Rats; D012559:Schizophrenia / Q000188:drug therapy / Q000473:pathology
chemical_list: D063309:2',3'-Cyclic Nucleotide 3'-Phosphodiesterase; D014150:Antipsychotic Agents; D051792:Basic Helix-Loop-Helix Proteins; D001569:Benzodiazepines; D003987:Dibenzothiazepines; D006220:Haloperidol; D009419:Nerve Tissue Proteins; D000077152:Olanzapine; D000076104:Oligodendrocyte Transcription Factor 2; D000069348:Quetiapine Fumarate; C498633:Olig1 protein, rat; C522729:Olig2 protein, rat; C571339:Cnp protein, rat
keywords: CNP; Differentiation; Haloperidol; Olanzapine; Olig1; Olig2; Oligodendrocyte; Proliferation; Quetiapine; Schizophrenia